Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024

Rhea-AI Summary

Vericel (NASDAQ: VCEL), a prominent player in sports medicine and severe burn care, announced its participation in the Truist Securities MedTech Conference. The event will feature a fireside chat with President and CEO Nick Colangelo, along with CFO Joe Mara, scheduled for 2:30 p.m. ET on June 18, 2024. Investors and interested parties can access the webcast through Vericel's Investor Relations website.

Positive

• Vericel's involvement in the Truist Securities MedTech Conference highlights its leadership role in advanced therapies for sports medicine and severe burn care.
• The participation of top executives, including Nick Colangelo and Joe Mara, underscores the company's strategic focus and could positively influence investor confidence.

Negative

• The press release lacks detailed financial or clinical data updates, leaving investors without new information on the company's performance or progress.
• No significant business developments or specific achievements were mentioned, which may leave shareholders seeking more substantial updates.

CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid^® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact: 
Julie Downs
media@vcel.com 

FAQ

When is Vericel participating in the Truist Securities MedTech Conference?

Vericel is participating on June 18, 2024.

Who will represent Vericel at the Truist Securities MedTech Conference?

Nick Colangelo, President and CEO, and Joe Mara, CFO, will represent Vericel.

How can I watch Vericel's presentation at the Truist Securities MedTech Conference?

A webcast of the presentation will be available on the Investor Relations section of the Vericel website.

What time is Vericel's fireside chat at the Truist Securities MedTech Conference?

The fireside chat is scheduled for 2:30 p.m. ET.

What is Vericel's stock symbol?

Vericel's stock symbol is NASDAQ: VCEL.